Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

In this study, adults with persistent facial erythema of rosacea showed significantly greater improvement when treated with once-daily oxymetazoline cream compared to a vehicle, and using baseline photographs in assessments enhanced the accuracy by reducing perceived vehicle effects.

This article discusses the history and terminology of toxic epidermal necrolysis but reports no new clinical results.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study found that etifoxine pretreatment reduced neuroinflammation and improved cognitive function in LPS-induced neuroinflammation in mice, potentially through increased neurosteroid synthesis and reduced apoptosis.

This study evaluated a microemulsion-based flushing fluid made with castor oil that effectively removed 84.85% of mud cake formed by drilling fluid, highlighting its Newtonian fluid behavior and high wettability inversion capability.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

Minoxidil can cause deadly skin reaction; monitor patients closely.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

In this case report, the authors suggest that methotrexate-induced rheumatoid papular eruption is a rare side effect of methotrexate, resolved after discontinuation, which may be linked to rheumatic conditions.

This study designed fast-dissolving Minoxidil tablets to improve patient compliance and found that formulations containing 6% croscarmellose sodium were optimal, showing rapid in-vitro dispersion and effective drug release without drug interaction.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

In this study, oral etretinate resulted in increased hair length and loss of beading in a childhood monilethrix case, while the scalp's keratosis pilaris persisted.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.

In a mice model of atopic dermatitis, this study reported that a formulated cromolyn sodium oleate gel significantly reduced scab size and provided better healing than dexamethasone, with fewer adverse effects.

In this study, divalproex sodium extended-release was found to be more tolerable and preferred by patients compared to the delayed-release formulation, with improved seizure control and psychiatric symptom relief.

This study investigated spanlastic nanovascular drug delivery systems and found that they can effectively enhance the transport and continuous release of medicines with small particle size, low polydispersity index, and satisfactory entrapment efficiency, showing potential as carriers for drug delivery.

This review found that 5α‐reductase inhibitors were associated with slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, and mood disorders compared to placebo, though their long-term effects remain unclear.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study found that minoxidil in Espumil Foam Base remains stable for at least 90 days when stored at room temperature and protected from light.

This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.

This article reviews the current status of oral retinoids in dermatology and reports no new clinical findings.

Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This report documents a case of dermatological toxicity associated with chronic minoxidil therapy, highlighting the emergence of a severe rash after three years of use, which recurred upon inadvertent rechallenge.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.